Company Update

Transgene Biotek Limited has informed that it is not required to submit a statement detailing any deviation in the use of funds from public, rights, or preferential issues for the quarter ended 30th June 2026. This is because the company did not conduct any such capital raising activities during this period.

For shareholders, this means there were no new shares issued via these routes, and therefore, no fund utilization report is necessary, ensuring clarity on the company’s capital structure without new offerings.